angiotensin II receptor type 1Genealiases: AG2S · AGTR1B · AT1 · AT1AR · AT1B · AT1BR
Q-omics provides the consensus-scored AGTR1 profile across patient tissues and cancer cell-line models. AGTR1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AGTR1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, AGTR1 RNA expression shows 19,392 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where AGTR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGTR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGTR1 survival associations across molecular data types. AGTR1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGTR1 RNA expression–survival associations across cancer types. High AGTR1 expression shows unfavorable associations in LUSC, OV, UCEC and SKCM, but favorable associations in KIRC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AGTR1 RNA expression.
This table summarizes AGTR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for AGTR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGTR1 shows lower tumor expression in BLCA, THCA, KIRP, KICH, COAD and LUSC. The BLCA box plot shows higher AGTR1 RNA expression in normal versus tumor tissue (log2 FC = −3.562, t-test p < 0.001).
This table shows molecular features associated with AGTR1 in patient tissues and cancer cell lines. In patient samples, AGTR1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, AGTR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
